The activity of chloroquine, halofantrine and pyrimethamine against the gametocytes and sporogonic stages of Plasmodium falciparum (strain NF54) was tested. Five-day-old gametocytes (stages I and II) from in vitro cultures were exposed to the drugs for 48 hours. The effect of the drugs on gametocyte development was assessed by counting gametocytes on days nine and 15 of culture and determining the infectivity of the drug-treated gametocytes to mosquitoes. Gametocytogenesis was partially inhibited by all three drugs; there were 71% of the number of gametocytes in drug-free control cultures in cultures with 3 x 10(-8) M chloroquine, 51% with 5 x 10(-8) M chloroquine, 78% with 5-7 x 10(-9) M halofantrine, and 48% with 10(-7) M pyrimethamine. Halofantrine- and pyrimethamine-treated gametocytes were found to be more infective to Anopheles stephensi than untreated controls. The three drugs were also administered to the mosquitoes, either in the first bloodmeal, which contained gametocytes from in vitro cultures, or in the second, parasite-free bloodmeal, given four days after infection. The sporontocidal activity of the drugs was evaluated by counting the number of oocysts on the midgut seven or eight days after infection, or the number of sporozoites in the salivary glands 15 days after infection. A sporontocidal effect was observed only when pyrimethamine was administered with the infective bloodmeal. Neither chloroquine nor halofantrine had any marked effect on sporogony at the concentrations tested.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00034983.1992.11812639DOI Listing

Publication Analysis

Top Keywords

chloroquine halofantrine
12
days infection
12
plasmodium falciparum
8
halofantrine pyrimethamine
8
gametocytes
8
anopheles stephensi
8
vitro cultures
8
three drugs
8
10-8 chloroquine
8
infection sporontocidal
8

Similar Publications

Resistance to Antimalarial Monotherapy Is Cyclic.

J Clin Med

January 2022

Drug Discovery Lab, Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.

Malaria is a prevalent parasitic disease that is estimated to kill between one and two million people-mostly children-every year. Here, we query PubMed for malaria drug resistance and plot the yearly citations of 14 common antimalarials. Remarkably, most antimalarial drugs display cyclic resistance patterns, rising and falling over four decades.

View Article and Find Full Text PDF
Article Synopsis
  • Hydroxychloroquine (HCQ) is commonly used to treat conditions like lupus and arthritis, and is being evaluated for COVID-19 treatment and prevention; this study focuses on its safety regarding a specific heart arrhythmia risk (TdP).
  • Mathematical modeling was used to assess the risk of TdP for HCQ, chloroquine (CQ), and other QT-prolonging drugs, finding that HCQ is most likely in the high-intermediate-risk category while CQ falls into the intermediate-risk category.
  • The combination of HCQ with other drugs like moxifloxacin and halofantrine increases the risk of heart complications, with the HCQ/HAL combination posing the highest
View Article and Find Full Text PDF

Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross.

Int J Parasitol Drugs Drug Resist

December 2020

Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 20892, USA. Electronic address:

Article Synopsis
  • The study investigates the drug response of Plasmodium falciparum strains to lumefantrine and mefloquine, focusing on genetic factors influencing susceptibility and resistance.
  • Drug response phenotypes were measured through half-maximal effective concentrations (ECs) and recovery days after lumefantrine exposure, revealing significant differences between two strains and their progeny.
  • The research found correlations between drug response and specific genetic polymorphisms in the PfMDR1, PfK13, and PfCRT proteins, suggesting these variations may impact the effectiveness of malaria treatments.
View Article and Find Full Text PDF

Objectives: To assess the efficacy of several repurposed drugs to prevent hospitalisation or death in patients aged 65 or more with recent symptomatic SARS-CoV-2 infection (COVID-19) and no criteria for hospitalisation.

Trial Design: Phase III, multi-arm (5) and multi-stage (MAMS), randomized, open-label controlled superiority trial. Participants will be randomly allocated 1:1:1:1:1 to the following strategies: Arm 1: Control arm Arms 2 to 5: Experimental treatment arms Planned interim analyses will be conducted at regular intervals.

View Article and Find Full Text PDF

Background: Policymakers have recognized that proprietary patent medicine vendors (PPMVs) can provide an opportunity for effective scaling up of artemisinin-based combination therapy (ACT) since they constitute a major source of malaria treatment in Nigeria. This study was designed to determine the stocking pattern for anti-malarial medications, knowledge of the recommended anti-malarial medicine among PPMVs in Akinyele Local Government Area (LGA) of Oyo State, Nigeria and their perception on ways to improve PPMV adherence to stocking ACT medicines.

Methods: A cross-sectional survey was conducted among 320 PPMVs using a mixed method of data collection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!